WCLC 2025 - Posters & ePosters-PT2.17.05 Benefits of Adjuvant Alectinib in ALK+ Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System

PT2.17.05 Benefits of Adjuvant Alectinib in ALK+ Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System

Back to course

Pdf Summary

This study evaluates the benefits of adjuvant alectinib versus standard platinum-based chemotherapy (PbCH) in patients with resected ALK-positive early-stage non-small cell lung cancer (eNSCLC) within Spain’s National Healthcare System (NHS). ALK rearrangements occur in 3-5% of eNSCLC patients, a subgroup with high recurrence risk post-surgery. Currently, approximately 50% of resected eNSCLC patients experience disease recurrence within 5 years.<br /><br />Using an epidemiological model projecting over a 10-year horizon, the analysis compares two scenarios: adjuvant alectinib (assumed to reach 98% market share by year 5) versus current adjuvant PbCH (4 cycles). Recurrence probabilities were based on disease-free survival and overall survival data from the ALINA clinical trial, with recurrence management costs per case estimated at €137,026 from recent Spanish studies.<br /><br />Results show that adjuvant alectinib could reduce the total number of recurrences from 680 to 341 over 10 years, potentially avoiding 339 recurrences. This translates to nearly €46.4 million euros saved in recurrence management costs compared to PbCH. Sensitivity analyses indicate a savings range of €42.3 to €49.3 million.<br /><br />The study highlights the substantial clinical and economic benefit of adopting alectinib as standard adjuvant therapy in ALK-positive eNSCLC patients in Spain, supporting improved patient outcomes through reduced disease relapses and significant cost savings for the healthcare system. This evidence underscores the value of targeted therapies in preventing advanced disease and optimizing resource use in oncology care. The work was funded by Roche Farma, conducted with Hygeia Consulting, and reflects input from multiple Spanish oncology centers.

Asset Subtitle

Javier de Castro

Meta Tag

Speaker Javier de Castro

Topic Global Health, Health Services, and Health Economics

Keywords

adjuvant alectinib

platinum-based chemotherapy

ALK-positive non-small cell lung cancer

early-stage NSCLC

Spain National Healthcare System

disease recurrence

ALINA clinical trial

recurrence management costs

epidemiological model

targeted therapies